Overview

Evaluation of Metabolic Profile of OC000459

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

An open label study in 9 male and 9 female healthy subjects to determine the pharmacokinetics of parent compound and metabolite after eight days of dosing.

Phase:

Phase 1

Details

Lead Sponsor:

Atopix Therapeutics, Ltd.

Collaborator:

Simbec Research

Treatments:

Indoleacetic Acids